Merck applies for US emergency authorization of COVID-19 tablet

The Merck emblem is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Picture

Merck & Co Inc mentioned on Monday it has utilized for emergency use authorization in america for its oral drug to deal with mild-to-moderate sufferers of COVID-19. The therapy, molnupiravir, has been developed with Ridgeback Biotherapeutics. If approved, it could be the primary oral antiviral remedy.

Knowledge launched final week confirmed that molnupiravir might halve the probabilities of demise or being hospitalized for these most liable to contracting extreme COVID-19.

Current medicine embody Gilead Sciences Inc’s infused antiviral remdesivir and generic steroid dexamethasone, each of that are usually solely given as soon as a affected person has already been hospitalized.

Monoclonal antibody medicine have thus far seen solely restricted uptake as a result of problem of their administration. 

See also  Moderna says COVID-19 vaccine pricing to make sure broad entry